6 results match your criteria: "National Research Centre for Hematology[Affiliation]"
Front Immunol
October 2022
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
FOXP1 is ubiquitously expressed in the human body and is implicated in both physiological and pathological processes including cancer. However, despite its importance the role of FOXP1 in T-cells has not been extensively studied. Although relatively few phenotypic and mechanistic details are available, FOXP1 role in T-cell quiescence and differentiation of CD4+ subsets has recently been established.
View Article and Find Full Text PDFCancers (Basel)
February 2022
Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Immunotherapy using chimeric antigen receptor (CAR) T cells is a promising option for cancer treatment. However, T cells and CAR-T cells frequently become dysfunctional in cancer, where numerous evasion mechanisms impair antitumor immunity. Cancer frequently exploits intrinsic T cell dysfunction mechanisms that evolved for the purpose of defending against autoimmunity.
View Article and Find Full Text PDFTher Adv Hematol
April 2020
Haemophilia Centre Rhine Main GmbH, Hessenring 13a, Geb. G, Mörfelden-Walldorf, 64546, Germany.
Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate®, a plasma-derived, double virus-inactivated, von Willebrand factor (VWF)-containing FVIII concentrate, has been used in clinics worldwide for over 20 years. First licensed in 1998 in Germany, octanate® is approved in over 80 countries for the prevention and treatment of bleeding and for surgical prophylaxis in patients with haemophilia A, and in over 40 countries for immune tolerance induction (ITI).
View Article and Find Full Text PDFTer Arkh
January 2017
National Research Centre for Hematology, Ministry of Health of Russia, Moscow, Russia.
Aim: to estimate the spread of weak D antigen types of the Rhesus system in the citizens of the Russian Federation and a possibility of serologically identifying these types.
Subjects And Methods: The red blood cells and DNA of people with weakened expression of D antigen were investigated using erythrocyte agglutination reaction in salt medium (2 methods); agglutination reaction in the gel columns containing IgM + IgG anti-D antibodies, indirect antiglobulin test with IgG anti-D antibodies (2 methods); polymerase chain reaction to establish the type of weak D.
Results: A rhesus phenotype was determined in 5100 people in 2014-2015.
Appl Radiat Isot
June 2010
National Research Centre for Hematology, Russian Academy of Medical Sciences, Moscow, Russia.
A comparative analysis of the distribution and the frequency of multiaberrant cells (MAC) among lymphocytes in different categories of low dose (up to 0.5 Gy) irradiated people was carried out. The highest MAC frequency was observed in people exposed to alpha-radiation (Pu, Rn) and in cosmonauts.
View Article and Find Full Text PDFNature
July 1993
Laboratory of Physiology of Hematopoiesis, National Research Centre for Hematology, Moscow, Russia.
It is widely accepted that during murine embryogenesis, totipotent haematopoietic stem cells first originate in the yolk sac, then migrate to the fetal liver and finally colonize the bone marrow shortly before birth. This view is based on in vitro studies showing that yolk sac cells can differentiate into various haematopoietic lineages and in vivo studies showing that yolk sac contains spleen colony-forming units (CFU-S) beginning at day 8 of gestation. However, some investigators have failed to find statistically significant numbers of CFU-S arising from day 9 yolk sac and, although one group reported that yolk sac could repopulate the haematopoietic system of W mutant mice, others have failed to confirm yolk sac-derived repopulation of adults.
View Article and Find Full Text PDF